UM  > 健康科學學院
Pathway-based analysis of genome-wide siRNA screens reveals the regulatory landscape of app processing
Camargo L.M.1; Zhang X.D.1; Loerch P.1; Caceres R.M.1; Marine S.D.1; Uva P.1; Ferrer M.1; De Rinaldis E.1; Stone D.J.1; Majercak J.1; Ray W.J.1; Chen Y.-A.5; Shearman M.S.1; Mizuguchi K.5
2015-02-27
Source PublicationPLoS ONE
ISSN19326203
Volume10Issue:2
AbstractThe progressive aggregation of Amyloid-β (Aβ) in the brain is a major trait of Alzheimer's Disease (AD). Aβ is produced as a result of proteolytic processing of the β-amyloid precursor protein (APP). Processing of APP is mediated by multiple enzymes, resulting in the production of distinct peptide products: the non-amyloidogenic peptide sAPPα and the amyloidogenic peptides sAPPβ, Aβ40, and Aβ42. Using a pathway-based approach, we analyzed a large-scale siRNA screen that measured the production of different APP proteolytic products. Our analysis identified many of the biological processes/pathways that are known to regulate APP processing and have been implicated in AD pathogenesis, as well as revealing novel regulatory mechanisms. Furthermore, we also demonstrate that some of these processes differentially regulate APP processing, with some mechanisms favouring production of certain peptide species over others. For example, synaptic transmission having a bias towards regulating Aβ40 production over Aβ42 as well as processes involved in insulin and pancreatic biology having a bias for sAPPβ production over sAPP α. In addition, some of the pathways identified as regulators of APP processing contain genes (CLU, BIN1, CR1, PICALM, TREM2, SORL1, MEF2C, DSG2, EPH1A) recently implicated with AD through genome wide association studies (GWAS) and associated meta-analysis. In addition, we provide supporting evidence and a deeper mechanistic understanding of the role of diabetes in AD. The identification of these processes/pathways, their differential impact on APP processing, and their relationships to each other, provide a comprehensive systems biology view of the "regulatory landscape" of APP.
DOI10.1371/journal.pone.0115369
URLView the original
Language英語
Fulltext Access
Citation statistics
Cited Times [WOS]:9   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionFaculty of Health Sciences
Affiliation1.Merck Research Laboratories
2.Centro di Ricerca
3.Merck Serono, SA Billerica
4.Takeda Pharmaceuticals U.S.A., Inc.
5.National Institute of Biomedical Innovation
6.National Center for Advancing Translational Sciences
7.Novartis Institutes for BioMedical Research, Inc.
8.King's College London
9.Boehringer Ingelheim Pharmaceuticals, Inc.
Recommended Citation
GB/T 7714
Camargo L.M.,Zhang X.D.,Loerch P.,et al. Pathway-based analysis of genome-wide siRNA screens reveals the regulatory landscape of app processing[J]. PLoS ONE,2015,10(2).
APA Camargo L.M..,Zhang X.D..,Loerch P..,Caceres R.M..,Marine S.D..,...&Mizuguchi K..(2015).Pathway-based analysis of genome-wide siRNA screens reveals the regulatory landscape of app processing.PLoS ONE,10(2).
MLA Camargo L.M.,et al."Pathway-based analysis of genome-wide siRNA screens reveals the regulatory landscape of app processing".PLoS ONE 10.2(2015).
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Camargo L.M.]'s Articles
[Zhang X.D.]'s Articles
[Loerch P.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Camargo L.M.]'s Articles
[Zhang X.D.]'s Articles
[Loerch P.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Camargo L.M.]'s Articles
[Zhang X.D.]'s Articles
[Loerch P.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.